Tony Berberabe, MPH

Articles

CAR T-Cell Therapy Is Safe, Feasible in Outpatient Setting for NHL

June 14th 2024

The administration of CAR T-cell therapy in the outpatient setting was deemed feasible and safe in patients with relapsed/refractory NHL.

CAN-2409 Plus Valacyclovir Shows Favorable Tolerability, Induces Immune Responses in NSCLC

June 4th 2024

In patients with NSCLC refractory to anti-PD(L)1 therapy, CAN-2409 (adenovirus) plus valacyclovir co-administered with ICI therapy showed acceptable tolerability and potential for immune modulation

Extended Lymphadenectomy Shows No DFS, OS Benefit During Radical Cystectomy in Urothelial Cancer

May 3rd 2024

Concurrent radical cystectomy and extended lymph node dissection did not show benefit vs standard lymph node dissection in muscle invasive urothelial cancer.

Tislelizumab Plus Chemo Generates Responses in Locally Advanced Cervical Cancer

March 16th 2024

Neoadjuvant tislelizumab in combination with chemotherapy was safe and produced responses in patients with locally advanced cervical cancer.

Presence of ctDNA Does Not Predict Benefit of Adjuvant Chemotherapy in Stage II Colon Cancer

January 22nd 2024

Adjuvant chemotherapy did not improve circulating tumor DNA clearance in patients with stage II colon cancer with baseline circulating tumor DNA.

MRD Positivity Correlates With Allogeneic Transplant Benefits in NPM1-Mutated AML

December 10th 2023

The presence of molecular minimal residual disease following induction chemotherapy can be used to determine patients with NPM1-mutated acute myeloid leukemia who may benefit from allogeneic transplant in first remission, including those with FLT3 ITD–mutated disease.

Epcoritamab Monotherapy Demonstrates High Response Rates in High-Risk Relapsed/Refractory CLL

October 9th 2023

Treatment with subcutaneous epcoritamab-bysp elicited rapid and durable responses, including an encouraging complete response rate, and manageable safety in high-risk patients with relapsed/refractory chronic lymphocytic leukemia.

Forimtamig Delivers Responses in Relapsed/Refractory Multiple Myeloma

September 29th 2023

Forimtamig monotherapy generated high overall response rates and durable responses in all subgroups of patients with relapsed/refractory multiple myeloma enrolled in a phase 1a dose-escalation trial.

Improved Molecular Understanding of AP/BP MPN Better Informs Management Approaches

September 8th 2023

Developing an optimal treatment strategy for patients with accelerated- or blast-phase myeloproliferative neoplasms requires consideration of a patient's ability to tolerate intensive induction therapy, their eligibility for allogeneic stem cell transplant.

Ongoing Investigations of Nelabarine and Daratumumab May Improve Outcomes in T-ALL

September 8th 2023

Investigating the addition of novel agents to cytotoxic chemotherapy may help prevent relapse in patients with T-cell acute lymphoblastic leukemia by bolstering the efficacy of these standard frontline therapies.

Phase 3 CLL12 Data Support Watch-and-Wait Approach in Early-Stage CLL

June 11th 2023

Ibrutinib did not prolong survival vs placebo and is linked with increased susceptibility to bleeding in patients with asymptomatic early-stage chronic lymphocytic leukemia, suggesting that a watch-and-wait approach should continue as the standard for this population.

Daratumumab Plus Induction Therapy Reduces Stem Cell Yield in Multiple Myeloma

June 9th 2023

The addition of daratumumab to frontline induction therapy prior to peripheral blood stem cell collection reduced the number of patients with newly diagnosed multiple myeloma who were able to meet their stem cell collection goals on first attempt.

Doxorubicin/Zalifrelimab/Balstilimab Generates Activity in Soft Tissue Sarcoma

June 5th 2023

Treatment with doxorubicin plus zalifrelimab and balstilimab produced a favorable 6-month progression-free survival rate in patients with difficult-to-treat soft tissue sarcoma subtypes unlikely to respond to doxorubicin or immune checkpoint inhibitor monotherapy.

PHE855 Generates High Response and MRD Negativity Rates in Relapsed/Refractory Myeloma

June 3rd 2023

The CAR T-cell therapy PHE885 produced responses and high minimal residual disease negativity rates with no new safety signals in patients with relapsed/refractory multiple myeloma.

Atezolizumab/Cabozantinib Fails to Elicit Benefit Over SOC in Second-line Metastatic NSCLC

April 2nd 2023

Second-line atezolizumab plus cabozantinib did not generate a clinical benefit over standard-of-care docetaxel in patients with metastatic non–small cell lung cancer previously treated with immune checkpoint inhibitors and chemotherapy.

Pembrolizumab Plus Chemotherapy Improves Survival in dMMR/pMMR Advanced Endometrial Cancer

March 28th 2023

Pembrolizumab plus standard-of-care chemotherapy, followed by maintenance pembrolizumab, reduced the risk of disease progression or death vs chemotherapy alone in patients with mismatch repair–deficient and mismatch repair–proficient advanced or recurrent endometrial cancer.

Bevacizumab Plus TAS-102 Increases Survival and DCR in mCRC

January 21st 2023

Third-line bevacizumab plus trifluridine/tipiracil demonstrated a survival and disease control benefit vs trifluridine/tipiracil alone in patients with refractory metastatic colorectal cancer and all clinically relevant subgroups.

Low-Dose Lenalidomide Reduces Risk of Transfusion Dependency, Provides Clonal Response and Safety Benefits in MDS

December 12th 2022

Low doses of lenalidomide prolonged time to and decreased the risk of transfusion dependency and induced quality clonal responses with no increases in progression rate or clonal evolution in patients with low-risk myelodysplastic syndrome.

ARV-471 Monotherapy Demonstrates Clinical Benefit in ER+/HER2- Advanced Breast Cancer

December 8th 2022

ARV-471 monotherapy elicited a significant clinical benefit rate in patients with estrogen receptor–positive/HER2-negative locally advanced or metastatic breast cancer who had undergone prior hormonal therapy and chemotherapy, including those with ESR1 mutations.

REGN5458 Elicits Promising Responses, Safety in Relapsed/Refractory Myeloma

August 27th 2022

REGN5458 produced durable responses with low rates of cytokine release syndrome in patients with relapsed/refractory multiple myeloma.